Congress Speaker, 2017

Prof. M. JOHN CHAPMAN
PhD, DSc, FESC

Research Professor at the University of Pierre and Marie Curie, Director Emeritus of the INSERM Dyslipidemia and Atherosclerosis Research Unit at the Pitié-Salpétrière University Hospital in Paris, France.

Professor Chapman undertook his graduate studies at the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, and at the Gladstone Foundation for Cardiovascular Disease in the same city. As President of the European Society of Atherosclerosis from 2009 to 2013, he actively supported the development of new Joint Guidelines for the Management of Dyslipidemia with the European Society of Cardiology launched in 2011. As Co-Chair of the EAS Consensus Panels and Consensus Papers, he has spearheaded initiatives on Lipoprotein Lp(a) and on atherogenic high triglyceride / low HDL dyslipidemia as major cardiovascular risk factors, on the underdiagnosis and undertreatment of heterozygous familial hypercholesterolemia (FH), on homozygous FH, on FH in children and adolescents with emphasis on optimal detection and treatment, on the genetics of hypertriglyceridemic states, on plant sterols and stanols in the management of dyslipidemia and prevention of cardiovascular disease. The most recent Consensus papers have focussed on intolerance to statin therapy and notably statin-associated muscle symptoms, and on the causality of LDL in atherosclerotic cardiovascular disease.

His research has contributed to further understanding of the metabolic and structural heterogeneity of LDL and Lp(a) particles at the interface with their atherogenicity , and to structure-function relationships in HDL subpopulations in healthy subjects and in dyslipidemic states associated with high cardiovascular risk. The mechanisms of action of pharmacological agents (statins, fibrates, CETP inhibitors, PCSK9 inhibitors) in attenuating atherogenic dyslipidemia are a central focus of his interests. His present research is focussed on (i) the intravascular metabolism and pharmacotherapeutic modulation of the atherogenic apoB-containing lipoproteins, and (ii) the structural heterogeneity, molecular composition (proteome and lipidome) and functionality of native and recombinant HDL in health and disease, with a view to optimisation of their anti-atherosclerotic potential. Prof Chapman is Laureate of the European Lipid Science Award for 2014, and of the Antonio M. Gotto Jr Award in Atherosclerosis Research from the International Atherosclerosis Society for 2015.